

IND SAFETY REPORT: FOLLOW-UP #1TO: *Division of Biologic Oncology Products, Center for Drug Evaluation and Research, FDA*

FAX: 301-796-9849

1. IND NUMBER
79212. AGENT NAME
Bevacizumab (rhuMAb VEGF)3. DATE
October 28, 20094. SPONSOR
Division of Cancer Treatment and Diagnosis, National Cancer Institute5. REPORTER=S NAME, TITLE, AND INSTITUTION
Kevin Conlon, MD-Senior Investigator for Investigational Therapeutics 3, CTEP, DCTD, NCI6. PHONE NUMBER
301-496-11967. FAX NUMBER
301-402-04288. PROTOCOL NUMBER (AE #)
E5103 (AE # 1720941)9. PATIENT IDENTIFICATION
5234010. AGE
5711. SEX
Female

12. DESCRIPTION OF ADVERSE EVENT

The patient is a 57-year-old female with invasive breast carcinoma who developed grade 4 abdominal pain while on a phase 3 study using the investigational agent bevacizumab/placebo in combination with doxorubicin, cyclophosphamide, and paclitaxel. She began her first course of treatment on April 15, 2009, and received the last dose of bevacizumab/placebo on April 15, 2009 (Cycle 1, Day 1). On April 27, 2009 (Cycle 1, Day 13), the patient left the clinic and while driving home she began to experience severe abdominal pain. Once she arrived home, she contacted the clinic and was instructed to go to the ER. Vital signs upon arrival were: blood pressure 105/55 mg/Hg, pulse 96, respiratory rate 20, and temperature 102.6° F. Upon physical examination, the patient's abdomen was soft with diffuse tenderness in the middle of the lower abdomen. The patient's bowel sounds were hypoactive. A CT scan of the abdomen with contrast revealed free fluid within the pelvis and diverticulosis. On April 28, 2009 (Cycle 1, Day 14), the patient was admitted to the hospital. She was placed on bowel rest and antibiotics. On May 1, 2009 (Cycle 1, Day 17), the patient was discharged. Additional information has been requested. There is a reasonable possibility that the experience may have been caused by the drug.

13. DOSE, ROUTE, AND SCHEDULE

Bevacizumab/Placebo 10 mg/kg IV over 30-90 minutes on Day 1 (Cycles 1-4); Cycle = 14 days
Bevacizumab/Placebo 15 mg/kg IV over 30-90 minutes on Day 1 (Cycles 5-8); Cycle = 21 days

14. DATES OF TREATMENT The patient started the investigational therapy on April 15, 2009, and received the last dose of bevacizumab/placebo on April 15, 2009 (Cycle 1, Day 1).

15. ACCRUAL AND IND EXPERIENCE Number of patients enrolled in NCI-sponsored clinical trials using bevacizumab = 21385. The adverse event is known to be associated with the investigational agent, bevacizumab.

16. COMMENTS The following are also included in the regimen:

Cycles 1-4: doxorubicin: 60 mg/m² IVP on Day 1, cyclophosphamide: 600 mg/m² IV over 20-30 min on Day 1 (last administered on April 15, 2009 [Cycle 1, Day 1]) and filgrastim 5 mcg/kg SQ on Days 2-11 (last administered on April 19, 2009 [Cycle 1, Day 5]).

Cycles 5-8: paclitaxel: 80 mg/m² IV over 1 hour on Days 1, 8, and 15

FOLLOW-UP: BASED UPON FURTHER INVESTIGATION, THE SENIOR INVESTIGATOR HAS DECIDED THAT THIS EVENT IS EITHER NOT SERIOUS OR UNEXPECTED AND THUS DOES NOT REQUIRE EXPEDITED REPORTING.

0002